CD147 handles lipid: a new role for anti-cancer target | Zendy

Daniel J. Felmlee | Zendy; Thomas F. Baumert | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CD147 handles lipid: a new role for anti-cancer target

Author(s) -

Daniel J. Felmlee,

Thomas F. Baumert

Publication year - 2016

Publication title -

translational cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.254

H-Index - 30

eISSN - 2219-6803

pISSN - 2218-676X

DOI - 10.21037/tcr.2016.06.28

Subject(s) - immunosuppression , immunotherapy , hepatocellular carcinoma , cancer , medicine , liver cancer , cd8 , cancer immunotherapy , immune system , cancer research , immunology , oncology

The future of anti-cancer therapy is promising as immunotherapy strategies have been revolutionary in treatment of a number of cancers. However, some organs such as the liver are characterised by immunosuppression of CD4 + and CD8 + activity, necessitating alternative strategies for cancers in such tissues. This occurs at least partly through aberrant expression of alpha-fetoprotein that in turn dampens immune activation (1). Hepatocellular carcinoma (HCC) is the second leading cause of death from cancer worldwide (2). Complementary strategies to CD4 + and CD8 + T cell-mediated immunotherapies that specifically target HCC are needed for the future of effective and comprehensive cancer therapy. On the short-list for a molecular target for such a therapy is CD147/EMMPRIN.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research